Question explored with the scientific record
Shingles vax good for healthy 64 yr old man who had chickenpox as a child
For a healthy 64-year-old man, the shingles vaccine is a reasonable bet: it cuts your risk of a painful rash by about 97% for several years, but you will likely feel lousy for a day or two after each dose.
The evidence for the recombinant zoster vaccine (Shingrix) comes from two large, manufacturer-funded trials (ZOE-50 and ZOE-70) that followed people for about 3.5 years [3]. In adults 50 and older, two doses prevented 97.2% of shingles cases [3][4]. Protection lasted well: about 89% efficacy over nearly 10 years of follow-up [5]. The vaccine also reduced the risk of postherpetic neuralgia, the chronic nerve pain that can follow shingles, by about 91% [5]. These are real clinical outcomes, not just lab tests.
The trade-off is that the vaccine causes frequent short-term side effects. In the trials, about 60% of people reported injection-site reactions or systemic symptoms like fever and headache, lasting a median of 1-3 days [1][7]. A small safety signal for Guillain-Barré syndrome exists: about 3 extra cases per million doses [4]. For a healthy 64-year-old, the risk of shingles itself is real—about 3 in 1,000 per year at age 50, rising to about 10 in 1,000 by age 80 [2]—so the vaccine's benefit likely outweighs its temporary discomfort.
| Outcome | Without vaccine | With vaccine |
|---|---|---|
| Shingles cases per 1,000 people over ~3.5 years | ~9.1 [6] | ~0.3 [6] |
| Postherpetic neuralgia risk | ~15% of shingles cases [2] | Reduced by ~91% [5] |
| Short-term side effects (any) | ~3% with placebo [6] | ~60% [1] |
My call: the vaccine is effective and the evidence is solid, but the decision is yours. Confidence: high for short-term efficacy, moderate for long-term safety beyond 10 years.
Sources used 7
-
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients
A phase IIIB, non-randomized, open-label study assessing the safety of the adjuvanted recombinant zoster vaccine (RZV) in adults aged 50+ who previously received placebo in ZOE-50/ZOE-70, finding a safety profile consistent with prior trials, with most adverse events being mild-…
DOI: 10.1016/j.vaccine.2020.10.029 -
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster
A comprehensive review of varicella-zoster virus biology, latency and reactivation, and the epidemiology of herpes zoster, summarizing risk factors, immune mechanisms, complications (notably postherpetic neuralgia), viral genotyping, and vaccination implications across temperate…
DOI: 10.1016/S1386-6532(10)70002-0 -
Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy
RZV is highly effective against herpes zoster and its complications, with protection lasting at least 10 years across age groups and in immunocompromised populations, but policy decisions require additional considerations such as cost-effectiveness and disease burden data.
DOI: 10.3390/vaccines13030250 -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
What is Different about Recombinant Herpes Zoster Vaccine?
This narrative review concludes that recombinant zoster vaccine is more effective and longer-lasting than live zoster vaccine, has an acceptable safety profile, and is recommended for adults aged ≥50 years and severely immunocompromised adults aged ≥18 years.
DOI: 10.3904/kjm.2024.99.4.180 -
Efficacy of varicella (VZV) vaccination: an update for the clinician
Varicella vaccines dramatically reduce varicella incidence and severe disease, with newer zoster vaccines offering strong, age-independent protection while research into ORF7 and neuroattenuated strategies points toward next-generation vaccines.
DOI: 10.1177/2051013616655980 -
Healthy ageing: Herpes zoster infection and the role of zoster vaccination
This narrative review concludes that adjuvanted recombinant zoster vaccine prevents herpes zoster and postherpetic neuralgia, has a reassuring safety profile, and is a key action for healthy ageing.
DOI: 10.1038/s41541-023-00757-0